
1. Firm Overview & Global Regulatory Compliance Framework
2. Core Operational Philosophy & Global Project Competitive Advantages
1.Dual-standard design capability
All facility and equipment schemes simultaneously satisfy global cGMP rules and local national construction, environmental and occupational safety codes of host countries, eliminating costly design rework during local authority inspection and drug registration.
2.Vertically integrated domestic manufacturing & global supply chain
Self-owned sanitary equipment factory produces 316L stainless steel bioreactors, purification skids and CIP/SIP systems with full material traceability and FDA DMF-supportable certification; we coordinate global logistics, customs clearance and overseas on-site installation to shorten delivery cycles and cut overall CAPEX by 15%–30% compared with European/American engineering competitors.
3.Multidisciplinary international technical team
Our core team consists of bioprocess specialists, cleanroom architects, automation engineers and regulatory consultants with decades of overseas project experience, proficient in English, Arabic, Spanish and other mainstream business languages, providing seamless cross-cultural communication throughout all project phases.
4.Global full-lifecycle risk control system
Front-end FMEA hazard assessment tailored to regional regulatory requirements; standardized cross-border project management workflows for schedule, quality and cost control; dedicated overseas validation teams to complete IQ/OQ/PQ and regulatory audit preparation locally.
Compared with Western bioprocess engineering companies, we deliver equivalent GMP-compliant performance with more competitive total investment and flexible customized service modes, while outperforming regional small contractors in process depth, equipment self-manufacturing capacity and global compliance proficiency.
3. Four Core Global Project Service Modules & Standard Deliverables
1.International Consultancy & Conceptual Design Module
Provide cross-border site feasibility study, production capacity planning, risk-based facility master layout, BIM 3D process design and localization adjustment for host-country construction codes. Deliver bilingual DQ documents, global contamination control strategy reports and pre-regulatory gap assessment reports to guide early-stage project investment decisions for overseas clients.
2.Global EPCM Turnkey Delivery Module
Execute full-process engineering drawing design, global regulated procurement, cross-border shipping supervision, overseas cleanroom construction management, sanitary pipeline orbital welding and utility system integration. Adopt flexible lump-sum turnkey or EPCM management models adaptable to different overseas client investment management demands.
3.Custom Equipment Export & Overseas Installation Module
Manufacture process-tailored bioreactors, medium/buffer tanks, chromatography skids and automated control systems with full international certification; arrange containerized export, customs document preparation, and dispatch Chinese senior technicians to complete on-site assembly, SAT linkage testing and equipment operation training for local staff.
4.Cross-border CQV & Regulatory Compliance Module
Deploy localized validation teams to complete full-set IQ/OQ/PQ qualification on-site; compile English-language audit-ready validation master plans, batch records and technical dossiers to support FDA, EMA and local drug authority inspections; provide pre-audit simulation services to accelerate market approval progress.
4. Global Industrial Application & Worldwide After-Sales Support
We build a global 7×24 technical support network combining remote online troubleshooting and regional on-site service stations; offer long-term spare parts global supply, regular overseas facility risk re-evaluation, regional GMP operation training and process optimization follow-up consulting. By combining China’s advanced biomanufacturing engineering capacity with international regulatory expertise, we help global biopharma partners lower capital investment risks, shorten factory construction and validation cycles, and build fully compliant, stable and sustainable biologic production facilities worldwide.